特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経調節:深部脳刺激および迷走神経刺激デバイス市場

Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market

発行 Datamonitor Healthcare 商品コード 939982
出版日 ページ情報 英文 111 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
神経調節:深部脳刺激および迷走神経刺激デバイス市場 Neuromodulation: Deep Brain Stimulation and Vagus Nerve Stimulation Devices Market
出版日: 2020年05月08日 ページ情報: 英文 111 Pages
概要

運動障害やてんかんの治療に対応するニューロモデュレーションシステムの世界市場は、 2019年の12億米ドルから2024年には18億米ドルに拡大すると予測されており、この間のCAGRは8.5%になる見通しです。

当レポートは、世界のニューロモデュレーション市場を調査したもので、臨床応用の状況、脳深部電気刺激法(DBS)と迷走神経刺激療法(VNS)に対応する技術、市場の分析、関連企業のリストなどの情報を提供しています。

目次

エグゼクティブサマリー

  • DBSとVNSを合わせた市場
    • 市場成長要因と阻害要因
    • DBS市場
    • VNS市場
    • マーケットリーダー
  • 調査手法

第1章 臨床の概要

  • DBS
  • VNS
  • 運動障害
    • パーキンソン病
    • 本態性振戦
    • ジストニア
  • てんかん
  • 大鬱病性障害
  • 神経障害の有病率
  • 参考文献

第2章 DBSに対応する技術

  • 主な製品
    • Abbott
    • Boston Scientific
    • Medtronic
  • 参考文献

第3章 VNSに対応する技術

  • 主な製品
    • LivaNova
    • Medtronic
    • NeuroPace
  • 参考文献

第4章 市場分析

  • DBS装置市場
    • 市場予測: 世界
    • 市場予測:地域別
    • 成長促進要因と阻害要因
    • 市場シェア: 世界
    • 市場シェア:地域別
  • VNS装置市場
    • 市場予測: 世界
    • 市場予測:地域別
    • 成長促進要因と阻害要因
    • 市場シェア: 世界
    • 市場シェア:地域別
  • DBSとVNSを合わせた市場
  • 会社概要
    • Abbott
    • Boston Scientific
    • LivaNova
    • Medtronic
  • 参考文献

付録A:関連企業のリスト

目次
Product Code: #MDT20005

Overview

Global sales of neuromodulation systems for the treatment of movement disorders (Parkinson's disease, essential tremor, and dystonia) and epilepsy, which include implantable deep brain stimulation (DBS) and vagus nerve stimulation (VNS) devices, respectively, are expected to increase at a CAGR of approximately 8.5%, from nearly $1.2bn in 2019 to approximately $1.8bn in 2024. The highly competitive DBS and VNS segments-which contribute nearly one-third of the global $4.5bn+ neuromodulation market-are significantly underpenetrated, with substantial room for growth. The DBS/VNS markets are being driven by several positive factors, including: a long clinical history with a substantial reduction in debilitating symptoms, strong marketing and surgeon training efforts, and technological innovation (eg new directional lead technologies, precisely targeted stimulation, and therapy customization). The launch of next-generation DBS and VNS systems are further improving outcomes and providing patients with incurable neurological conditions a safe, effective, and long-term device-based therapy alternative.

The report provides the following useful information:

  • an overview of neuromodulation technology for the treatment of refractory neurological movement disorders and epilepsy
  • key epidemiology data on the prevalence of Parkinson's disease, essential tremor, dystonia, epilepsy, and depression
  • related product portfolios offered by leading manufacturers
  • top selling neuromodulation devices, as well as emerging products under development
  • in-depth market and competitive analyses.

Table of Contents

Executive Summary

  • i. Combined market
    • a. Selected market drivers and limiters
    • b. Deep brain stimulation devices segment
    • c. Vagus nerve stimulation devices segment
    • d. Market leaders
  • ii. Methodology
  • Exhibit ES-1: Deep brain stimulation and vagus nerve stimulation devices, combined market forecast ($m), by segment, 2019-24
  • Exhibit ES-2: Deep brain stimulation devices market, forecast sales by region ($m), 2019-24
  • Exhibit ES-3: Vagus nerve stimulation devices, forecast sales by region ($m), 2019-24

1. Clinical Overview

  • 1.1. Deep brain stimulation
  • 1.2. Vagus nerve stimulation
  • 1.3. Movement disorders
    • 1.3.1. Parkinson's disease
    • 1.3.2. Essential tremor
    • 1.3.3. Dystonia
  • 1.4. Epilepsy
  • 1.5. Major depressive disorder
  • 1.6. Prevalence of neurological disorders
  • 1.7. Bibliography
  • Exhibit 1-1: Diagram of Medtronic's deep brain stimulation system implantation
  • Exhibit 1-2: Diagram of vagus nerve stimulation therapy
  • Exhibit 1-3: Prevalence of movement disorders, epilepsy and depression

2. Deep Brain Stimulation Technology

  • 2.1. Selected products
    • 2.1.1. Abbott
    • 2.1.2. Boston Scientific
    • 2.1.3. Medtronic
  • 2.2. Bibliography
  • Exhibit 2-1: Implantable deep brain stimulation systems for movement disorders
  • Exhibit 2-2: Abbott's Infinity DBS system with proprietary directional leads
  • Exhibit 2-3: Boston Scientific's Vercise DBS portfolio, including new Vercise Gevia with Cartesia Directional Lead
  • Exhibit 2-4: Medtronic's Activa DBS systems
  • Exhibit 2-5: Medtronic's new Percept PC DBS system with BrainSense Technology
  • Exhibit 2-6: Medtronic DBS therapy indications

3. Vagus Nerve Stimulation Technology

  • 3.1. Selected products
    • 3.1.1. LivaNova
    • 3.1.2. Medtronic
    • 3.1.3. NeuroPace
  • 3.2. Bibliography
  • Exhibit 3-1: Vagus nerve stimulation using implantable VNS Therapy
  • Exhibit 3-2: Neuromodulation systems for the treatment of epilepsy
  • Exhibit 3-3: LivaNova's SenTiva VNS Therapy System
  • Exhibit 3-4: The anterior nucleus of the thalamus
  • Exhibit 3-5: The NeuroPace RNS System

4. Market Analysis

  • 4.1. Deep brain stimulation devices market
    • 4.1.1. Market forecast: global
    • 4.1.2. Market forecast: by region
    • 4.1.3. Market drivers and limiters
    • 4.1.4. Market share: global
    • 4.1.5. Market share: by region
  • 4.2. Vagus nerve stimulation devices market
    • 4.2.1. Market forecast: global
    • 4.2.2. Market forecast: by region
    • 4.2.3. Market drivers and limiters
    • 4.2.4. Market share: global
    • 4.2.5. Market share: by region
  • 4.3. Combined market
  • 4.4. Corporate profiles
    • 4.4.1. Abbott
    • 4.4.2. Boston Scientific
    • 4.4.3. LivaNova
    • 4.4.4. Medtronic
  • 4.5. Bibliography
  • Exhibit 4-1: Deep brain stimulation devices, global market forecast ($m), 2019-24
  • Exhibit 4-2: Deep brain stimulation devices market, estimated sales and share of revenues by region, 2019
  • Exhibit 4-3: Deep brain stimulation devices market, forecast sales by region ($m), 2019-24
  • Exhibit 4-4: Deep brain stimulation devices market, estimated global share by supplier, 2019
  • Exhibit 4-5: Selected noninvasive brain stimulation systems
  • Exhibit 4-6: Deep brain stimulation devices market ($m), estimated share by supplier and region, 2019
  • Exhibit 4-7: Vagus nerve stimulation devices, global market forecast ($m), 2019-24
  • Exhibit 4-8: Vagus nerve neurostimulation devices, estimated share of revenues by region, 2019
  • Exhibit 4-9: Vagus nerve stimulation devices, forecast sales by region ($m), 2019-24
  • Exhibit 4-10: Vagus nerve stimulation devices market, estimated global share by supplier, 2019
  • Exhibit 4-11: Vagus nerve stimulation devices market, estimated share by supplier and region, 2019
  • Exhibit 4-12: Combined deep brain stimulation and vagus nerve stimulation devices market, forecast sales by segment ($m), 2019-24
  • Exhibit 4-13: Abbott, revenues by segment, FY2019
  • Exhibit 4-14: Boston Scientific, revenues by segment, FY2019
  • Exhibit 4-15: LivaNova, revenues by segment, FY2019
  • Exhibit 4-16: Medtronic, revenues by segment, FY2019

Appendix A: company listing